BeiGene, Ltd.·4

Mar 4, 5:24 PM ET

BRANDICOURT OLIVIER 4

4 · BeiGene, Ltd. · Filed Mar 4, 2024

Insider Transaction Report

Form 4
Period: 2024-02-29
Transactions
  • Award

    Share Option (Right to Buy)

    2024-02-29+27,79427,794 total
    Exercise: $12.74Exp: 2034-02-28Ordinary Shares (27,794 underlying)
Footnotes (2)
  • [F1]The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares.
  • [F2]The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.

Documents

1 file
  • 4
    wk-form4_1709591065.xmlPrimary

    FORM 4